2.814EUR+1.66%Mkt Cap: 221.89M EURP/E: —Last update: 2026-05-14
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)20.10
PEG—
P/B1.85
P/S20.29
EV/EBITDA-37.08
EV/Revenue18.98
EPS (TTM)-0.03
EPS (Forward)0.14
Cash Flow & Leverage
FCF Yield-5.35%
FCF Margin-108.50%
Operating CF-2.36M EUR
CapEx (TTM)11.04M EUR
Net Debt/EBITDA1.90
Net Debt-10.61M EUR
Technical
SMA 502.797 (+0.6%)
SMA 2003.018 (-6.8%)
Beta0.43
S&P 52W Chg24.23%
Avg Vol (30d)256.65K
Avg Vol (10d)234.05K
Technical Indicators
RSI (14)51.6
MACD-0.0145
MACD Signal-0.0184
MACD Hist.+0.0039
BB Upper2.881 EUR
BB Middle2.797 EUR
BB Lower2.713 EUR
BB Width6.00%
ATR (14)0.0789 EUR
Vol Ratio (20d)0.77x
52W Range
2.55518% of range4.020
52W High4.020 EUR
52W Low2.555 EUR
Profitability
Gross Margin97.42%
EBITDA Margin-51.19%
Profit Margin-23.83%
Oper. Margin53.04%
ROE-2.21%
ROA-1.80%
Revenue Growth48.60%
Earnings Growth—
Balance Sheet
Debt/Equity0.06
Current Ratio1.95
Quick Ratio1.94
Book Value/Sh1.520 EUR
Cash/Share0.3660 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.77.51M
Float60.52M
Insiders21.27%
Institutions0.79%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)7.067 EUR
Target Range4.000 EUR – 12.00 EUR
# Analysts3
Company
Market Cap221.89M EUR
Enterprise Value207.51M EUR
Revenue (TTM)10.93M EUR
Gross Profit10.65M EUR
Net Income (TTM)-2.61M EUR
Revenue/Share0.1410 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees46
Last Price2.814 EUR
CountryES
SectorHealthcare
IndustryBiotechnology
ISINES0167733015